No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
333 |
4. Check minimum number of eventsNone |
333 |
5. Include endpointsNone |
333 |
6. Filter based on genotype QC (FinnGen only) |
323 |
Control definitions (FinnGen only)
- Control exclude
- E4_ENDOGLAND
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- E34
- Name in latin
- Syndroma carcinoides
Similar endpoints
↥List of similar endpoints to
Carcinoid syndrome
based on the number of shared cases.
Similar with more cases:
- Other endocrine disorders
- Disorders of other endocrine glands
- Endocrine, nutritional and metabolic diseases
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1609 | 854 | 744 |
| Only index persons | 1230 | 666 | 564 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.02 | 0.02 |
| Only index persons | 0.02 | 0.02 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 64.12 | 63.82 | 64.35 |
| Only index persons | 62.75 | 62.30 | 63.27 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 323 | 154 | 169 |
| Unadjusted period prevalence (%) | 0.07 | 0.05 | 0.08 |
| Median age at first event (years) | 62.48 | 60.87 | 63.94 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 333
- Matched controls
- 3330
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
E34.0
ICD-10 Finland
Carcinoid syndrome
+∞
307.7
312
*
130
Kela drug reimbursment
Malignant tumour
32.1
240.9
221
193
JFB00
NOMESCO Finland
Partial resection of small intestine
79.4
161.8
88
15
C78.7
ICD-10 Finland
Secondary malignant neoplasm of liver and intrahepatic bile duct
36.7
161.1
108
43
H01CB02
ATC
octreotide; parenteral
1077.5
145.7
132
*
C17.9
ICD-10 Finland
Malignant neoplasm: Small intestine, unspecified
523.4
138.9
129
*
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
24.6
134.9
106
62
H01CB03
ATC
lanreotide; parenteral
+∞
128.7
115
*
JN3CD
NOMESCO Finland
Abdominal CT examination both without and with contrast
26.5
124.5
93
48
JN4CD
NOMESCO Finland
Very extensive body CT
20.4
111.2
94
63
JN7AQ
NOMESCO Finland
Somatostatin receptor SPET med low dose CT
1280.9
100.6
93
*
XX7JT
NOMESCO Finland
Somatostatin isotope ablative therapy
+∞
96.7
88
*
JN4BD
NOMESCO Finland
Extensive body CT
10.2
95.7
148
243
JN3BD
NOMESCO Finland
Extensive abdominal CT
9.9
86.9
130
203
JN4AD
NOMESCO Finland
Body CT examination
9.0
80.5
131
224
JJ2AT
NOMESCO Finland
Biopsy of liver with ultrasound guidance
25.7
77.0
56
26
WD305
NOMESCO Finland
Simple therapy of methastized malignancy with biomodifiers
29.2
72.6
50
20
D37.7
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Other digestive organs
19.0
71.9
60
38
XX9AN
NOMESCO Finland
Complementary isotope examination or additional picture
+∞
71.5
66
*
WX302
NOMESCO Finland
Thoracal epidural anesthesy
11.3
62.3
73
81
JFB30
NOMESCO Finland
Right hemicolectomy
27.3
61.1
43
18
L01AX03
ATC
temozolomide; systemic
112.8
60.3
64
7
C17.2
ICD-10 Finland
Malignant neoplasm: Ileum
681.6
59.7
57
*
JN5ER
NOMESCO Finland
PET-CT of receptors in whole body
126.5
59.1
62
6
8240/3-C17.9
ICD-O-3
Neuroendocrine tumor, NOS, of small intestine, NOS
+∞
55.8
52
*
L01BC06
ATC
capecitabine; oral
10.4
54.0
66
77
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
8.5
52.0
77
114
D77
ICPC
Malignant digestive neopl other/NOS
95.4
51.8
56
7
A03FA01
ATC
metoclopramide; systemic, rectal
5.1
47.8
159
505
WD225
NOMESCO Finland
Demanding therapy of methastized malignancy with hormones
69.7
46.9
53
9
A04AA02
ATC
granisetron; systemic, transdermal
7.6
45.5
74
121
A09AA02
ATC
multienzymes (lipase, protease etc.); oral
13.5
45.5
45
38
D37.2
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Small intestine
93.3
44.2
48
6
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
6.3
42.1
84
169
D37.6
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Liver, gallbladder and bile ducts
16.9
40.5
35
23
JKA20
NOMESCO Finland
Cholecystectomy
11.6
39.5
43
42
JN1CG
NOMESCO Finland
Extensive MRI examination of upper part of abdomen with high intensity magnet
13.3
39.2
39
33
302
Kela drug reimbursment
Interferon alfa
+∞
38.3
36
*
133
Kela drug reimbursment
Severe chronic pancreatic insufficiency
15.8
37.0
33
23
WVA30, ,
SPAT
7.9
36.8
55
81
C10AC01
ATC
colestyramine; oral
11.2
35.2
39
39
T73
ICPC
Neoplasm endocrine other/unspecified
+∞
31.8
30
*
Z51.5
ICD-10 Finland
Palliative care
5.3
31.6
74
170
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
4.6
30.7
90
248
C17.8
ICD-10 Finland
Malignant neoplasm: Overlapping lesion of small intestine
+∞
30.7
29
*
JN7SN
NOMESCO Finland
Somatostatin receptor SPECT
+∞
30.7
29
*
L03AB05
ATC
interferon alfa-2b; parenteral
75.4
30.5
34
5
A79
ICPC
Malignancy NOS
12.6
29.5
30
26
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
6.3
28.2
52
95
WX602
NOMESCO Finland
Repeated or continuing anesthesia shots throug a catheter
5.7
27.6
57
116
K56.6
ICD-10 Finland
Other and unspecified intestinal obstruction
8.1
26.9
38
52
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
3.4
26.6
173
807
JN4SR
NOMESCO Finland
Very extensive PET-CT of receptors in whole body
281.3
26.1
26
*
JN7AN
NOMESCO Finland
Somatostatin receptor isotope imaging
+∞
25.3
24
*
N02AA05
ATC
oxycodone; systemic
3.6
25.3
114
421
E34.9
ICD-10 Finland
Endocrine disorder, unspecified
+∞
24.3
23
*
WX408
NOMESCO Finland
General anesthesy, balanced
3.3
24.2
139
595
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
3.2
24.2
156
715
C25.4
ICD-10 Finland
Malignant neoplasm: Endocrine pancreas
257.8
24.0
24
*
JN3AD
NOMESCO Finland
Abdominal CT examination
4.0
23.2
78
235
WZC00
NOMESCO Finland
Treatment plan or consultation
3.1
22.4
167
823
8249/3-C17.9
ICD-O-3
Neuroendocrine tumor, grade 2 of small intestine, NOS
+∞
22.1
21
*
JAH00
NOMESCO Finland
Laparotomy
6.8
20.6
34
55
XX9AD
NOMESCO Finland
Complementary CT
+∞
20.0
19
*
8240/3-C17.2
ICD-O-3
Neuroendocrine tumor, NOS, of ileum
111.7
19.8
21
*
UJF32
NOMESCO Finland
Coloscopy
2.9
19.4
139
658
C18.99
ICD-10 Finland
Malignant tumor in unspecified location in the colon other or unspecified histology
+∞
17.9
17
*
A50
ICPC
General and Unspecified, Medication/prescr/renewal
6.4
17.3
30
51
D37.9
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Digestive organ, unspecified
37.2
16.9
21
6
8246/3-C17.9
ICD-O-3
Neuroendocrine carcinoma, NOS, of small intestine, NOS
+∞
16.8
16
*
C17.0
ICD-10 Finland
Malignant neoplasm: Duodenum
167.5
15.6
16
*
D76
ICPC
Malignant neoplasm pancreas
30.3
15.4
20
7
JN4DD
NOMESCO Finland
Scout CT scan of torso
47.4
15.2
18
*
JN3AA
NOMESCO Finland
Abdominal X-ray examination without contrast
5.3
14.8
31
63
SPAT1254
SPAT
Administration of medicine
3.1
14.7
74
283
B03BA03
ATC
hydroxocobalamin; parenteral
4.3
14.7
41
106
C18.19
ICD-10 Finland
Malignant tumor in appendix other or unspecified histology
+∞
14.7
14
*
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
2.6
14.7
127
645
SPAT1256
SPAT
Intramuscular and subcutaneous injection
2.5
14.7
183
1100
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.5
14.7
202
1270
ZXD05
NOMESCO Finland
Urgent procedure
2.6
14.6
129
661
C25.9
ICD-10 Finland
Malignant neoplasm: Pancreas, unspecified
16.7
14.1
22
14
JN1DG
NOMESCO Finland
Very extensive MRI examination of upper part of abdomen with high intensity magnet
13.5
14.1
24
19
ZXE10
NOMESCO Finland
More than one and less than three hours
2.4
14.0
156
886
C18.09
ICD-10 Finland
Malignant tumor of caecum other or unspecified histology
78.4
13.7
15
*
158
Kela drug reimbursment
Everolimus
78.4
13.7
15
*
JN3DG
NOMESCO Finland
Very extensive MRI examination with high intensity magnet
35.7
13.6
17
5
340
Kela drug reimbursment
Everolimus
+∞
13.6
13
*
C25.0
ICD-10 Finland
Malignant neoplasm: Head of pancreas
12.2
13.5
24
21
WF049
NOMESCO Finland
Radiotherapy of metastasis
5.1
13.3
29
61
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
3.9
13.1
42
120
JAH01
NOMESCO Finland
Laparoscopy
5.4
13.1
27
54
JLC10
NOMESCO Finland
Distal pancreatectomy
72.7
12.7
14
*
C18.90
ICD-10 Finland
Malignant tumor in unspecified location in the colon without histology
72.7
12.7
14
*
2592A
ICD-9 Finland
Other endocrine disorders, Carcinoid syndrome
+∞
12.6
12
*
8249/3-C17.2
ICD-O-3
Neuroendocrine tumor, grade 2 of ileum
+∞
12.6
12
*
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
4.5
12.6
32
77
C17.1
ICD-10 Finland
Malignant neoplasm: Jejunum
134.9
12.5
13
*
R4190
NOMESCO Finland
Nutritional therapy
5.7
12.5
24
45
TPH04
NOMESCO Finland
Cathetrisation of vein
2.5
12.4
100
485
B81
ICPC
Anaemia vit B12/folate deficiency
4.9
12.4
28
61
JN3CG
NOMESCO Finland
Extensive MRI examination of abdomen with high intensity magnet
39.1
12.3
15
*
JFB20
NOMESCO Finland
Ileocaecal resection
22.3
12.1
17
8
C25.2
ICD-10 Finland
Malignant neoplasm: Tail of pancreas
67.4
11.7
13
*
R11
ICD-10 Finland
Nausea and vomiting
3.4
11.7
46
151
JF1AB
NOMESCO Finland
Passage examination of small bowell with X-ray
14.3
11.6
19
14
E340, C179,
ICD-10 Finland
+∞
11.5
11
*
WD505
NOMESCO Finland
Simple enzyme inhibitor or similar therapy of methastized malignancy
15.8
11.4
18
12
B01AB10
ATC
tinzaparin; parenteral
3.0
11.4
55
204
-50
ICPC
Medication/prescr/renewal
4.3
11.2
30
75
A04AA01
ATC
ondansetron; systemic, rectal
3.3
11.1
44
145
A55
ICPC
General and Unspecified, Local injection/infiltration
16.2
10.9
17
11
L01CB01
ATC
etoposide; systemic
18.6
10.8
16
9
OAB38
NOMESCO Finland
Psychosocial guidance and counselling
62.0
10.7
12
*
UJF92
NOMESCO Finland
Capsular endoscopy
9.7
10.7
21
23
TPH20
NOMESCO Finland
Insertion of central venous catheter through subclavian or brachiocephalic vein
5.1
10.2
22
46
JF1BD
NOMESCO Finland
Very extensive small bowel CT
17.4
10.0
15
9
107
Kela drug reimbursment
Pernicious anaemia
8.2
9.8
21
27
J01MA12
ATC
levofloxacin; systemic
2.3
9.7
86
430
B01AB04
ATC
dalteparin; parenteral
4.1
9.6
27
70
ZXE20
NOMESCO Finland
More than three and less than five hours
2.5
9.6
68
308
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
2.3
9.5
86
434
XX2RW, ,
NOMESCO Finland
18.2
9.5
14
8
ZXF10
NOMESCO Finland
Interruption caused by technical failure of equipment
31.0
9.5
12
*
8240/3-C18.2
ICD-O-3
Neuroendocrine tumor, NOS, of ascending colon
102.8
9.5
10
*
D13.7
ICD-10 Finland
Benign neoplasm: Endocrine pancreas
102.8
9.5
10
*
8240/3-C34.9
ICD-O-3
Neuroendocrine tumor, NOS, of lung, NOS
102.8
9.5
10
*
JN5SR
NOMESCO Finland
Very extensive PET-CT of receptors in upper body
+∞
9.4
9
*
E21.0
ICD-10 Finland
Primary hyperparathyroidism
+∞
9.4
9
*
8249/3-C80.9
ICD-O-3
Neuroendocrine tumor, grade 2 of unknown primary site
+∞
9.4
9
*
8249/3-C25.9
ICD-O-3
Neuroendocrine tumor, grade 2 of pancreas, NOS
+∞
9.4
9
*
JN5DR
NOMESCO Finland
PET-CT of upper body metabolism
9.9
9.4
18
19
UJF30
NOMESCO Finland
Ileoscopy through colon
2.8
9.2
49
192
C78.8
ICD-10 Finland
Secondary malignant neoplasm of other and unspecified digestive organs
37.8
9.1
11
*
H02AB02
ATC
dexamethasone; systemic
2.6
9.0
56
237
B01AB05
ATC
enoxaparin; parenteral
2.1
9.0
133
813
D13.1
ICD-10 Finland
Benign neoplasm: Stomach
8.3
9.0
19
24
TPH07
NOMESCO Finland
Cathetrisation of artery
2.6
9.0
57
244
S50
ICPC
Skin, Medication/prescr/renewal
24.8
9.0
12
5
601
Kela drug reimbursment
Severe malabsorption of nutrients, mainly fats
10.4
8.6
16
16
A02BC05
ATC
esomeprazole; systemic
2.0
8.5
155
1015
JJB10
NOMESCO Finland
Atypcal resection of liver
20.7
8.5
12
6
JJA20
NOMESCO Finland
Open biopsy of liver
92.3
8.5
9
*
L01EG02
ATC
everolimus; oral
+∞
8.4
8
*
8240/3-C16.9
ICD-O-3
Neuroendocrine tumor, NOS, of stomach, NOS
+∞
8.4
8
*
C80.98
ICD-10 Finland
Malignant tumor without specified localization other specified histology
+∞
8.4
8
*
E21.09
ICD-10 Finland
Other primary hyperparathyroidism
+∞
8.4
8
*
8240/3-C20.9
ICD-O-3
Neuroendocrine tumor, NOS, of rectum, NOS
+∞
8.4
8
*
ZXE30
NOMESCO Finland
More than five and less than seven hours
3.9
8.3
25
68
Z71.3
ICD-10 Finland
Dietary counselling and surveillance
4.1
8.3
23
59
C03CA01
ATC
furosemide; systemic
2.0
8.3
130
807
C77.2
ICD-10 Finland
Secondary and unspecified malignant neoplasm: Intra-abdominal lymph nodes
17.7
8.1
12
7
Z51.88
ICD-10 Finland
Other specified medical care
7.7
7.8
17
23
JLC30
NOMESCO Finland
Pancreatoduodenectomy
15.5
7.8
12
8
K80.0
ICD-10 Finland
Calculus of gallbladder with acute cholecystitis
4.0
7.7
22
58
ZXM00
NOMESCO Finland
Intraoperative use of ultrasonographic imaging
18.9
7.6
11
6
197
Kela drug reimbursment
Sunitinib
25.7
7.6
10
*
UJF45
NOMESCO Finland
Flexible sigmoidoscopy with biopsy
2.8
7.6
41
161
WZC30
NOMESCO Finland
Teaching
2.2
7.6
71
361
C18.91
ICD-10 Finland
Malignant tumor of unspecified location in colon invasive carcinoma
81.8
7.4
8
*
AA4CG
NOMESCO Finland
Extensive MRI examination of sella turcica with high intensity magnet
81.8
7.4
8
*
XX3DW
NOMESCO Finland
Time consuming IT work
2.4
7.4
56
260
C78.6
ICD-10 Finland
Secondary malignant neoplasm of retroperitoneum and peritoneum
11.2
7.4
13
12
1522B
ICD-9 Finland
Malignant neoplasm of small intestine, including duodenum, Ileum[NEOPLASMA MALIGNUM ILEI,ALIA DEFINITA SEU NUD]
+∞
7.3
7
*
8240/3-C25.9
ICD-O-3
Neuroendocrine tumor, NOS, of pancreas, NOS
+∞
7.3
7
*
JLC11
NOMESCO Finland
Laparoscopic distal pancreatectomy
+∞
7.3
7
*
8246/3-C80.9
ICD-O-3
Neuroendocrine carcinoma, NOS, of unknown primary site
+∞
7.3
7
*
1CB02, ,
NOMESCO Finland
+∞
7.3
7
*
JKA21
NOMESCO Finland
Laparoscopic cholecystectomy
2.5
6.9
47
207
D50.9
ICD-10 Finland
Iron deficiency anaemia, unspecified
2.9
6.9
34
127
C79.5
ICD-10 Finland
Secondary malignant neoplasm of bone and bone marrow
6.3
6.9
17
28
L01XE10
ATC
[U] everolimus
40.9
6.8
8
*
S55
ICPC
Skin, Local injection/infiltration
40.9
6.8
8
*
KH1AD
NOMESCO Finland
CT of urinary organs
4.2
6.7
18
45
D75
ICPC
Malignant neoplasm colon/rectum
10.3
6.6
12
12
I36.1
ICD-10 Finland
Nonrheumatic tricuspid (valve) insufficiency
6.4
6.5
16
26
N02AX02
ATC
tramadol; systemic, rectal
1.8
6.5
158
1108
D50
ICPC
Digestive, Medication/prescr/renewal
71.2
6.4
7
*
T50
ICPC
Metabolic, Medication/prescr/renewal
71.2
6.4
7
*
WD515
NOMESCO Finland
Demanding therapy of malignancy with enzyme inhibitors and similar treatments
14.7
6.4
10
7
ZX120
NOMESCO Finland
Intravenous
2.5
6.4
43
188
R10.1
ICD-10 Finland
Pain localized to upper abdomen
2.1
6.3
70
378
WD205
NOMESCO Finland
Therapy of methastized malignancy with hormones
11.3
6.3
11
10
JJB60
NOMESCO Finland
Other excsion of three or more segments of liver
+∞
6.3
6
*
C26.0
ICD-10 Finland
Malignant neoplasm: Intestinal tract, part unspecified
+∞
6.3
6
*
8246/3-C25.9
ICD-O-3
Neuroendocrine carcinoma, NOS, of pancreas, NOS
+∞
6.3
6
*
Z03.80
ICD-10 Finland
Observation for other suspected diseases and conditions
5.9
6.2
16
28
166
Kela drug reimbursment
Dalteparin and tinzaparin (treatment for more than 6 months)
10.3
6.1
11
11
JL5BG
NOMESCO Finland
MRI examinaiton of bile and pancreas ducts with high intesity magnet
5.7
6.1
16
29
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.0
6.0
69
377
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
231
12
626.19
307.65
10.0
3.3
364.13
60.50
nmol/l
8.18
231
12
251
32
315.47
307.65
10.9
2.6
20.20
8.65
nmol/l
0.91
246
32
60
82
8.71
43.03
1.5
1.5
234.81
272.69
ug/g
0.63
43
48
107
291
4.94
37.84
2.3
2.3
0.22
0.21
g/l
0.90
102
273
113
352
4.35
33.10
3.5
4.5
12.47
45.32
ug/l
0.79
87
301
206
993
3.82
31.51
8.2
3.6
2.34
2.35
mmol/l
0.31
194
863
235
1269
3.89
29.49
9.0
5.0
35.59
35.32
g/l
0.37
228
1192
188
962
3.19
24.03
4.7
3.1
889.41
1245.64
ng/l
1.24
170
835
258
1613
3.66
23.04
18.8
9.7
3.59
4.12
e9/l
3.57
241
1413
240
1454
3.33
22.19
7.9
6.9
1.21
1.21
mmol/l
0.04
175
1233
227
1346
3.16
21.50
6.8
6.1
1.22
1.21
mmol/l
0.87
212
1204
76
244
3.74
20.46
4.0
2.9
97.12
192.48
ng/l
3.17
68
218
75
244
3.68
19.75
5.5
3.5
1.22
1.22
mmol/l
0.51
75
209
215
1280
2.92
19.41
10.6
5.7
3.19
2.91
%
0.77
207
1190
218
1314
2.91
19.10
10.9
5.9
25.71
26.98
%
0.96
210
1225
212
1294
2.76
17.53
10.7
5.7
58.14
57.59
%
0.25
204
1209
92
394
2.84
14.97
2.4
2.3
20.66
22.20
%
0.43
82
341
164
941
2.46
14.54
3.4
2.6
50.73
62.91
u/l
1.58
153
866
218
1443
2.48
13.79
16.9
14.1
1.21
1.28
inr
0.89
100
416
194
1226
2.40
13.52
23.9
10.0
0.00
0.00
e9/l
0.23
175
1010
249
1762
2.64
13.48
5.9
3.3
77.65
52.64
u/l
2.16
239
1630
99
472
2.56
12.81
3.1
3.6
0.80
0.82
mmol/l
0.49
93
445
95
457
2.51
11.97
2.4
2.3
12.12
12.80
umol/l
0.37
88
427
56
206
3.07
11.80
1.7
1.7
—
—
—
0
0
152
915
2.22
11.27
3.9
3.7
31.25
32.23
u/l
0.19
146
871
124
706
2.21
10.38
2.3
2.1
3.33
3.19
mg/l
0.21
104
612
70
313
2.57
10.14
4.6
3.3
—
—
—
0
0
21
49
4.51
8.53
3.7
3.5
56.29
58.84
%
0.31
21
49
110
638
2.08
8.48
3.1
2.6
4.41
4.34
e6/l
0.04
105
573
167
1124
1.97
8.47
3.1
2.2
70.11
76.76
nmol/l
2.09
151
978
20
47
4.46
8.05
3.3
2.9
3.89
4.76
e9/l
1.00
20
47
106
642
1.96
7.05
2.0
1.8
115294551.72
7576196.72
pmol/l
0.45
85
528
25
81
3.26
6.46
2.3
1.4
—
—
—
0
0
21
61
3.61
6.40
1.5
2.6
13.92
15.87
%
—
10
28
126
845
1.79
5.90
3.6
3.2
0.27
0.46
e6/l
1.07
107
638
21
65
3.38
5.83
1.1
1.4
—
—
—
0
0
177
1315
1.74
5.76
3.0
2.8
—
—
—
0
0
52
261
2.18
5.67
2.3
2.6
31.87
32.11
u/l
0.01
47
223
231
1859
1.79
5.59
5.5
4.5
544.83
2302.88
e6/l
—
6
34
61
330
2.04
5.47
2.4
3.2
9.04
10.12
umol/l
0.15
53
300
249
2066
1.81
5.24
4.7
3.7
14.53
14.93
pmol/l
1.64
229
1819
151
1103
1.68
5.01
3.2
2.5
175.33
148.37
ug/l
0.58
140
1002
60
338
1.95
4.78
3.2
4.4
216.98
254.50
u/l
2.17
54
317
40
194
2.21
4.74
2.7
3.2
104.37
75.77
ng/l
0.94
35
173
149
1102
1.64
4.60
3.7
3.2
—
—
—
0
0
36
173
2.21
4.36
2.3
3.8
1.63
1.87
mmol/l
0.10
25
134
156
1208
1.55
3.74
2.3
2.0
90.21
96.01
pmol/l
0.74
100
622
37
192
2.04
3.71
2.5
3.6
5.24
5.11
kpa
0.46
37
187
293
2654
1.87
3.44
33.0
14.4
76.00
77.05
ml/min/173m2
0.42
282
2204
302
2774
1.95
3.21
29.6
15.4
27.20
24.63
mg/l
0.62
270
2197
10
25
4.09
3.11
1.5
1.2
—
—
—
0
0
151
1197
1.48
3.06
4.5
3.9
41.65
35.78
ng/l
0.12
125
912
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
21
94
2.32
3.03
2.3
2.8
0.30
0.33
u/ml
0.24
12
47
12
38
3.24
2.88
1.2
1.3
—
—
—
0
0
19
87
2.26
2.62
1.2
1.2
—
—
—
0
0
6
11
5.53
2.55
1.2
1.2
141.83
45.88
u/l
—
6
11
6
11
5.53
2.55
1.2
1.2
224.17
127.92
u/l
—
6
11
80
579
1.50
2.47
2.2
1.7
1503.12
1232.20
nmol/l
1.06
52
427
10
32
3.19
2.45
5.0
8.2
6.67
6.20
mmol/l
—
10
27
6
12
5.07
2.41
2.8
1.8
27.67
28.00
umol/l
—
6
12
97
735
1.45
2.38
1.7
1.6
21.06
20.95
nmol/l
0.02
84
611
67
475
1.51
2.28
3.1
3.1
2.95
2.19
e6/l
0.20
40
266
67
479
1.50
2.19
1.8
1.8
—
—
—
0
0
263
2824
0.67
2.17
4.7
5.4
2.41
2.68
mmol/l
4.27
229
2564
91
694
1.43
2.13
3.0
2.3
—
—
—
0
0
11
43
2.61
2.10
1.5
1.9
90.44
89.53
%
0.34
11
43
245
2659
0.70
2.06
3.9
4.3
1.35
1.27
mmol/l
0.87
209
2397
100
786
1.39
1.96
4.1
4.2
0.00
0.00
estimate
-0.00
66
265
44
633
0.65
1.94
4.0
4.1
1.02
1.02
kg/l
0.37
11
94
9
34
2.69
1.88
1.3
1.7
—
—
—
0
0
5
12
4.21
1.83
2.0
1.5
51.40
68.97
ug/l
—
5
12
256
2744
0.71
1.81
4.4
4.7
1.44
1.46
mmol/l
0.28
222
2488
8
29
2.80
1.80
1.5
1.2
—
—
—
0
0
259
2762
0.72
1.66
4.4
4.7
4.30
4.57
mmol/l
3.38
223
2525
7
26
2.73
1.59
1.4
1.8
—
—
—
0
0
229
2081
1.32
1.56
4.0
4.2
16.46
12.75
mm/h
2.04
208
1891
271
2528
1.39
1.53
5.5
4.6
1.87
1.98
mu/l
0.75
249
2260
10
47
2.16
1.35
1.3
1.7
—
—
—
0
0
70
554
1.33
1.29
1.2
1.2
0.79
1.44
u/ml
0.83
17
149
10
48
2.12
1.29
1.2
1.4
—
—
—
0
0
10
48
2.12
1.29
1.2
1.4
—
—
—
0
0
11
55
2.03
1.29
1.2
7.5
—
146.38
—
0
8
13
70
1.89
1.25
1.2
1.8
—
—
—
0
0
12
64
1.91
1.19
5.1
4.6
32.17
31.62
mg/l
—
6
38
5
20
2.52
1.15
1.0
1.2
—
—
—
0
0
5
20
2.52
1.15
1.0
1.2
—
—
—
0
0
163
1455
1.24
1.13
2.2
2.6
—
—
—
0
0
280
2659
1.33
1.12
8.6
6.2
41.23
40.49
mmol/mol
0.74
264
2452
79
948
0.78
1.12
3.7
4.6
23.27
20.91
%
0.79
39
472
11
189
0.57
1.04
1.6
1.7
—
—
—
0
0
5
22
2.29
1.03
2.4
3.3
68.80
66.94
u/ml
—
5
22
64
517
1.29
1.03
3.0
2.9
0.92
1.07
e6/l
0.27
38
304
10
54
1.88
0.97
2.8
3.2
14.50
30.24
u/ml
—
10
54
16
101
1.61
0.95
1.9
1.6
—
—
—
0
0
7
37
1.91
0.94
1.6
1.4
—
—
—
0
0
10
167
0.59
0.87
2.6
2.8
0.84
1.27
%
—
10
167
8
46
1.76
0.83
1.5
1.0
—
—
—
0
0
0
24
0.00
0.79
0.0
1.2
—
162.70
—
0
24
0
25
0.00
0.79
0.0
1.0
—
555.60
—
0
15
0
25
0.00
0.79
0.0
1.0
—
36.18
—
0
13
10
161
0.61
0.77
2.4
2.8
0.82
0.68
%
—
10
161
9
53
1.72
0.76
1.3
1.8
—
—
—
0
0
123
1102
1.18
0.76
4.6
4.1
—
—
—
0
0
17
116
1.49
0.76
1.1
1.0
—
—
—
0
0
7
38
1.86
0.74
1.6
1.4
—
—
—
0
0
7
38
1.86
0.74
1.6
1.4
—
—
—
0
0
7
38
1.86
0.74
1.6
1.4
—
—
—
0
0
7
38
1.86
0.74
1.6
1.4
—
—
—
0
0
153
1399
1.17
0.73
5.8
5.1
0.00
0.00
estimate
-0.00
69
271
7
39
1.81
0.73
1.6
1.4
—
—
—
0
0
16
109
1.49
0.72
2.1
1.7
—
—
—
0
0
5
93
0.53
0.68
1.2
2.3
—
—
—
0
0
7
43
1.64
0.67
1.4
3.1
—
1265.40
—
0
5
7
43
1.64
0.67
1.1
1.8
—
—
—
0
0
16
112
1.45
0.64
3.6
1.8
—
—
—
0
0
11
71
1.57
0.63
1.3
1.7
—
—
—
0
0
10
152
0.65
0.62
1.0
1.3
—
56.95
—
0
14
106
1173
0.86
0.62
4.6
5.2
1.82
2.64
ug/l
1.59
94
1049
151
1394
1.15
0.62
4.3
3.9
0.00
0.00
estimate
0.50
74
289
153
1418
1.15
0.58
4.3
3.9
0.00
0.00
estimate
-0.00
72
261
8
54
1.49
0.57
1.1
1.8
—
—
—
0
0
43
360
1.22
0.55
5.8
9.4
1.26
1.35
mmol/l
0.04
35
292
12
170
0.69
0.55
1.8
2.6
—
19.61
—
0
11
6
38
1.59
0.54
5.7
4.4
—
—
—
0
0
15
108
1.41
0.54
3.7
2.9
—
—
—
0
0
46
389
1.21
0.54
4.3
4.7
34.00
31.61
%
0.76
32
255
303
2962
1.25
0.53
25.4
11.2
27.70
25.62
u/l
1.47
297
2845
31
378
0.80
0.52
9.7
7.6
—
—
—
0
0
11
75
1.48
0.51
1.1
1.7
—
—
—
0
0
7
106
0.65
0.49
1.1
2.1
253.57
292.90
ug/l
—
7
99
10
68
1.49
0.47
1.5
1.4
—
—
—
0
0
68
605
1.16
0.46
1.8
1.8
1.71
1.35
mg/l
0.55
50
483
5
32
1.57
0.42
3.2
2.2
—
—
—
0
0
5
32
1.57
0.42
2.8
2.1
—
—
—
0
0
0
15
0.00
0.41
0.0
1.1
—
1.06
—
0
9
0
15
0.00
0.41
0.0
2.2
—
—
—
0
0
0
19
0.00
0.39
0.0
1.0
—
—
—
0
0
9
66
1.37
0.38
1.1
1.1
—
13.01
—
0
8
63
566
1.14
0.38
2.7
3.7
96.51
285.88
ng/l
1.28
55
468
6
41
1.47
0.36
1.3
1.1
—
—
—
0
0
40
349
1.17
0.36
1.2
1.4
—
—
—
0
0
6
44
1.37
0.34
1.0
1.7
—
—
—
0
0
6
44
1.37
0.34
1.0
1.7
—
—
—
0
0
6
44
1.37
0.34
1.2
1.2
—
—
—
0
0
85
784
1.11
0.34
1.6
1.7
1.47
1.33
mmol/l
0.89
64
639
6
47
1.28
0.32
1.2
1.8
—
—
—
0
0
103
963
1.10
0.32
3.5
3.8
9.58
6.86
mg/mmol
0.21
59
612
11
84
1.32
0.30
1.6
1.2
—
—
—
0
0
38
339
1.14
0.27
1.6
1.7
—
—
—
0
0
308
3042
1.17
0.26
44.7
23.0
38.50
40.14
%
5.76
295
2837
308
3043
1.16
0.26
44.5
22.8
4.25
4.48
e12/l
10.72
303
2957
49
446
1.12
0.25
1.2
1.3
13.72
41.16
iu/ml
3.53
18
132
32
283
1.14
0.25
1.4
1.7
1.64
1.57
%
0.23
27
243
38
341
1.13
0.25
1.6
1.8
—
—
—
0
0
308
3044
1.16
0.25
44.8
22.9
127.57
135.51
g/l
14.38
303
2994
11
137
0.80
0.25
1.6
1.2
130.36
188.16
u/ml
0.29
11
124
80
753
1.08
0.22
3.0
2.8
374.89
9939.20
umol/l
4.34
72
640
0
11
0.00
0.21
0.0
1.0
—
9.62
—
0
11
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
5
43
1.17
0.21
1.2
1.8
—
—
—
0
0
0
14
0.00
0.20
0.0
2.5
—
13.62
—
0
14
0
14
0.00
0.20
0.0
1.4
—
—
—
0
0
11
132
0.83
0.18
1.5
1.6
—
—
—
0
0
7
62
1.13
0.17
1.0
1.2
—
1.04
—
0
5
10
119
0.84
0.15
1.3
1.5
—
—
—
0
0
11
95
1.16
0.12
1.2
1.2
—
—
—
0
0
12
136
0.88
0.11
1.7
1.3
—
—
—
0
0
11
96
1.15
0.10
1.2
1.2
—
—
—
0
0
65
675
0.95
0.10
3.1
3.1
0.73
0.76
ug/l
0.19
44
455
41
430
0.95
0.09
1.2
1.2
1.60
13.15
u/ml
2.16
15
161
6
55
1.09
0.09
1.7
1.5
—
—
—
0
0
19
175
1.09
0.08
1.6
1.6
—
—
—
0
0
7
64
1.10
0.08
1.9
1.9
—
—
—
0
0
7
66
1.06
0.08
1.4
1.5
—
—
—
0
0
7
66
1.06
0.08
1.0
1.2
—
—
—
0
0
9
86
1.05
0.07
1.3
1.7
—
—
—
0
0
18
189
0.95
0.03
1.5
1.4
—
—
—
0
0
29
282
1.03
0.02
4.3
3.8
1.38
2.05
mmol/l
0.30
20
232
30
297
1.01
0.00
1.4
1.4
—
—
—
0
0
276
2764
0.99
0.00
6.9
4.9
6.41
6.07
mmol/l
4.02
259
2490
8
81
0.99
0.00
1.6
1.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.4
—
7.44
—
0
7
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.4
—
38.43
—
0
7
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
6
67
0.89
-0.00
1.2
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
7
69
1.01
-0.00
1.0
1.3
—
2.91
—
0
12
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.4
—
1.30
—
0
5
5
59
0.85
-0.00
1.4
1.3
—
—
—
0
0
9
94
0.96
-0.00
1.9
1.8
—
163.33
—
0
6
0
9
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
7
71
0.99
-0.00
1.0
1.3
—
1.88
—
0
12
0
8
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint E4_CARCISDR and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_CARCISDR | 4.015 [3.24, 4.98] | < 0.001 |
| Birth year | 0.993 [0.98, 1.0] | 0.136 |
During the follow-up period (1.1.1998 — 31.12.2019), 304 out of 704 females with E4_CARCISDR died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_CARCISDR | 3.911 [3.06, 4.99] | < 0.001 |
| Birth year | 0.989 [0.98, 1.0] | 0.034 |
During the follow-up period (1.1.1998 — 31.12.2019), 305 out of 623 males with E4_CARCISDR died.
Mortality risk
Mortality risk for people of age
years, who have E4_CARCISDR.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.313% | 0.692% |
| 5 | 2.093% | 4.777% |
| 10 | 5.068% | 11.321% |
| 15 | 9.75% | 20.778% |
| 20 | 16.571% | 33.927% |
Relationships between endpoints
↥Index endpoint: E4_CARCISDR – Carcinoid syndrome
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data